AZD5363

capivasertib · AstraZeneca

Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for AZD5363, covering 2016-05-25 to 2025-12-31. Get the full timeline:

Most recent: Clinical Trial Update: mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian [Phase 1]